8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_____________________________________________________________ 

FORM 8-K

 _____________________________________________________________ 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): May 7, 2013

_____________________________________________________________  

MAXWELL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

_____________________________________________________________ 

Delaware	1-15477	95-2390133
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

3888 Calle Fortunada

San Diego, California 92123

(Addresses of principal executive offices, including zip code)

(858) 503-3300

(Registrant’s telephone number, including area code)

 _____________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 7, 2013, the Board of Directors (the "Board") of Maxwell Technologies, Inc. (the “Company”) appointed David Schlotterbeck to serve as a director of the Company, effective immediately. In addition, Mr. Schlotterbeck was appointed to the Board's Audit Committee.

The Company's Certificate of Incorporation and Bylaws provide for its Board to be divided into three classes, with each class having a three-year term. Mr. Schlotterbeck will be a member of the second class of directors, with a term of office expiring at the Company's next annual meeting of stockholders expected to be held in 2013.

Mr. Schlotterbeck will participate in the Company's standard compensation program for non-employee directors, as described in the Company's proxy statement filed with the Securities and Exchange Commission on March 30, 2012, except that the number of shares to be granted as an annual restricted stock unit award will be calculated by dividing $85,000 by the closing stock price, increased from $60,000 in 2012. Mr. Schlotterbeck will also enter into the Company's standard form of indemnification agreement.

The Company issued a press release announcing the appointment of Mr. Schlotterbeck on May 8, 2013, a copy of which is attached to this report as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release issued by Maxwell Technologies, Inc. on May 8, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MAXWELL TECHNOLOGIES, INC.
By:	/s/ Kevin S. Royal
	Kevin S. Royal
	Chief Financial Officer

Date: May 8, 2013

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by Maxwell Technologies, Inc. on May 8, 2013

EX-99.1

Exhibit 99.1

NEWS RELEASE

For Immediate Release

May 8, 2013

DAVID SCHLOTTERBECK JOINS MAXWELL TECHNOLOGIES' BOARD

SAN DIEGO, Calif. - Maxwell Technologies Inc. (Nasdaq: MXWL) announced today that David Schlotterbeck, a seasoned medical technology executive, has been appointed to the company's board of directors. In addition, Mr. Schlotterbeck was appointed to the board's audit committee.

Most recently, Schlotterbeck served as chairman of the board of directors and chief executive officer of Aperio Technologies, Inc. since November 2011. Before joining Aperio, he was chairman and chief executive officer of CareFusion, a leading global medical technology company, from September 2009 to February 2011. Previously, he was vice chairman of Cardinal Health and chief executive officer of their Clinical and Medical Products business. Earlier in his career Schlotterbeck held executive leadership roles at Alaris Medical Systems, Pacific Scientific Company, Vitalcom, Inc. and Nellcor, Inc. He is currently a member of the board of directors of Juniper Networks, Inc.

“We are delighted that Mr. Schlotterbeck has agreed to join Maxwell's board,” said Mark Rossi, chairman of the board. “His extensive business experience and contacts in the medical technology industry will make him a valuable resource and sounding board as we continue to pursue new avenues for growth.”

Maxwell is a leading developer and manufacturer of innovative, cost-effective energy storage and power delivery solutions. Our ultracapacitor products provide safe and reliable power solutions for applications in consumer and industrial electronics, transportation and telecommunications. Our high-voltage grading and coupling capacitors help to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution and measurement of high-voltage electrical energy. Our radiation-mitigated microelectronic products include power modules, memory modules and single board computers that incorporate powerful commercial silicon for superior performance and high reliability in aerospace applications.

Media & Investor Contact: Michael Sund +1 (858) 503-3233; msund@maxwell.com

###